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Abstract
Background: iPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte
antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic
transplantation of iPSC derived cell therapies. Cord blood banks offer an extensive source of HLA-typed cells
suitable for reprogramming to iPSC. Several initiatives worldwide have been undertaken to create national and
international iPSC haplobanks that match a significant part of a population.
Methods: To create an iPSC haplobank that serves the Spanish population (IPS-PANIA), we have searched the
Spanish Bone Marrow Donor Registry (REDMO) to identify the most frequently estimated haplotypes. From the top
ten donors identified, we estimated the population coverage using the criteria of zero mismatches in HLA-A, HLA-B,
and HLA-DRB1 with different stringencies: high resolution, low resolution, and beneficial mismatch.
Results: We have calculated that ten cord blood units from homozygous donors stored at the Spanish cord blood
banks can provide HLA-A, HLA-B, and HLA-DRB1 matching for 28.23% of the population.
Conclusion: We confirm the feasibility of using banked cord blood units to create an iPSC haplobank that will
cover a significant percentage of the Spanish and international population for future advanced therapy
replacement strategies.
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Introduction
Induced pluripotent stem cells (iPSC) hold great promise
in the field of regenerative medicine due to their cap-
acity to both self-renew and differentiate into any cell-
type of the human body. Unlike embryonic stem cells,
iPSC are free of ethical concerns and allow the autolo-
gous application of cell replacement therapies [1, 2].
There has been extensive research and development in
the field to create safe iPSC and protocols to differenti-
ate them into clinically relevant cells for cell therapy ap-
plications. This research effort culminated in 2015 with
the first successful clinical trial in Japan that used iPSC
derived retinal pigmented epithelial cells (RPE) in an
age-related macular degeneration (AMD) patient (RIKE
N trial) [3]. However, the high cost and lengthy process
of iPSC production could make the use of iPSC prohibi-
tive for many applications. Consequently, the idea of
using clinically matched iPSC for HLA-A, HLA-B, and
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HLA- DRB1 as an allogeneic treatment became more
widespread [4].
Although MHC (major histocompatibility complex)
class I and II molecules are potentially immunogenic,
HLA-A, HLA-B, and HLA–DRB1 are the strongest de-
terminants of rejection of an allogeneic transplant [5].
The effect of HLA-A, HLA-B, and HLA-DRB1 mismatch
on solid organ transplant rejection has been extensively
documented [6]. It is important to note that HLA
matching for solid organ transplantation mainly takes
into account HLA-A, HLA-B, and HLA-DRB1 loci at a
low-resolution level [7].
The level of HLA-matching requirements ranges de-
pending on the type of transplant, with a minimum
score of 9/10 (HLA-A, HLA-B, HLA-C, HLA-DRB1,
HLA-DQB1) for bone marrow transplantation of unre-
lated donors, a minimum score of 6/8 (HLA-A, HLA-B,
HLA-C, HLA-DRB1) for cord blood [8] to kidney trans-
plants in which several degrees of “beneficial match” are
considered, from one mismatch in HLA-A or HLA-B to
just matching HLA-DRB1 alone [9]. Currently, for
hematopoietic progenitor transplantation, the common
use is high-resolution sequencing (two fields) of five
HLA loci [10] using Next Generation Sequencing (NGS)
for typing.
The relevance and stringency of HLA-matching for
iPSC-derived cells for clinical transplantation has been
discussed extensively [11]. Unlike transplantation of
hematopoietic progenitors, iPSC derivatives do not
have contaminating immune cells and therefore the
level of compatibility required is measured only for
host vs. graft because the graft does not have in this
case the ability to react against the host mismatched
HLA antigens. HLA-A, HLA-B, and HLA-DRB1
matching have shown to confer a clear advantage
over totally allogeneic transplant, with different de-
grees of immunological responses observed indicating
the need for immunosuppression [4, 12].
Banking of HLA-typed pluripotent cells for matching a
wide proportion of a population was first proposed for
embryonic stem cells [13]. The authors also proposed the
use of homozygous donors for common HLA-A, HLA-B,
and HLA-DRB1 haplotypes as a way to provide HLA
match for a reasonable percentage of the target population
with a limited number of cell lines. Later, with the appear-
ance of iPSC, Nakatsuji and colleagues proposed the use
of banked cord blood as a source of HLA-typed cells for
the construction of HLA homozygous iPSC banks (haplo-
banks) [14]. It was estimated that a haplobank with only
30 iPSC lines would be able to cover 82.2% of the Japanese
population and 50 lines, 90.7% [14]. Other studies have
calculated the coverage of haplobanks for the UK popula-
tion [15], South Korea [16], China [17], and the USA [18].
iPSC haplobanks created from cord blood and peripheral
blood donors are already a reality in South Korea and
Japan [16, 19, 20].
The HLA haplotype landscape in Spain has been in-
vestigated before with small cohorts of patients and
healthy individuals [21–23] and a larger cohort of 5458
units of cord blood from the Barcelona Cord Blood
Bank, HLA-typed in high resolution [24].
The Spanish project IPS-PANIA aims at creating an
iPSC haplobank of at least seven clinical-grade lines to
provide maximum coverage to the Spanish population.
To identify the haplotypes providing maximum coverage
(probability of zero mismatches in HLA-A, HLA-B, and
HLA-DRB1), we have searched a large cohort of 32,000
adult bone marrow donors and calculated the estimated
coverage for a study population of 418,981 individuals
including cord blood donors plus bone marrow donors
from REDMO registry. We have concluded that a haplo-
bank of seven lines would cover 23.69% of the Spanish
population and ten lines would cover 28.23%.
Materials and methods
Study cohort and ethics approval
The REDMO includes the HLA typing of all cord blood
donations and all the adult bone marrow donors of the
Spanish population. For population coverage studies, the
target population consisted of all the cord blood plus all
the adult bone marrow donors in REDMO. The consult-
ation of the HLA data was approved by the Ethics Com-
mittee for Research with Medicines from Vall d’Hebron
Hospital (Barcelona, Spain) and the Transplantation and
Regenerative Medicine Commission of the Spanish Na-
tional Health System.
HLA typing and haplotype frequency determination
High-resolution typing was performed by Sanger se-
quencing in an ABI PRISM 3130xl Genetic Analyzer
(Thermo Fisher) and/or NGS in a MiSeq platform (Illu-
mina) or in Ion GeneStudio S5 System (Thermo Fisher)
for HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DRB3/4/5,
HLA-DQB1, and HLA-DPB1 genes. The resulting se-
quences were analyzed using Assign 4.7.1 (CareDX),
Type Stream Visual (One Lambda), and NGSengine
(GenDX, 2.16), depending on the used procedure. Low
resolution was performed using a PCR-SSO (Luminex)
based method for HLA-A, B, C, DRB1, and DQB1 genes.
The expectation-maximization algorithm implemented
in the Arlequin software (version 3.5.2.2) [25] was used
to estimate maximum-likelihood haplotype frequencies,
considering the high-resolution (4-digit) allelic frequen-
cies of three (A, B, and DRB1) and five HLA genes (A,
B, C, DRB1, and DQB1), from 30,000 and 27,000, re-
spectively, randomly selected adult subjects of the
REDMO project.
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Screening and selection of HLA haplotype homozygous
donors
All the cord blood units in REDMO were studied for the
identification of potential HLA-A, HLA-B, and HLA-
DRB1 homozygous cord blood donors. Selection and
classification of homozygous units were performed by
simple counts with Microsoft Excel.
Calculation of match coverage
To estimate the Spanish population HLA matching
coverage of a 10 iPSC haplobank, we counted the num-
ber individuals with zero mismatches in HLA-A, HLA-B,
and HLA-DR when compared with the top ten haplo-
types selected by frequency. The population cohort was
composed of the combined data of the adult bone mar-
row donors and cord blood donors in the REDMO col-
lection. The calculation was done either in two digits
HLA typing (low plus high resolution originally) on
418.980 individuals or in four digits (only high reso-
lution) on 56,798 individuals. The haplotype match
benefit (coverage) in the whole sample (including adult
bone marrow donors and cord blood donors) was esti-
mated with an in-house, iterative algorithm in R. Briefly,
in each iteration, the estimated haplotype that matched
the highest number of subjects was identified. Then, the
best haplotype and all matched individuals were ex-
tracted from the dataset and coverage was recomputed
in the remaining data. The matching was based on the
concordance of the A, B, and DRB1 alleles of the esti-
mated homozygous haplotypes with at least one of the
two alleles of these loci in each individual. To calculate
the coverage allowing for mismatch in one or two alleles
(beneficial match), the same strategy was applied, but
one or two mismatches in any HLA loci was tolerated.
In all cases, the cumulative percentage of coverage was
calculated by dividing the number of matched individ-




A cohort of 30,000 randomized high-resolution HLA
typing adult bone marrow donors from the REDMO
identified a total of 8478 different haplotypes for HLA-
A, HLA-B, and HLA-DRB1 (Fig. 1a and Supplementary
Excel file for the complete list). Five of them presented a
frequency 1% or higher, namely A*29:02~B*44:
03~DRB1*07:01 (3.12%), A*01:01~B*08:01~DRB1*03:01
(2.48%), A*30:02~B*18:01~DRB1*03:01 (1.99%), A*03:
01~B*07:02~DRB1*15:01 (1.34%), and A*33:01~B*14:
02~DRB1*01:02 (1.00%). Haplotype frequencies show a
steep decline after the first five (Fig. 1b).
We performed the same analysis for five genes, namely
HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1
with a 27,000 cohort from the REDMO registry. Only
the top six positions corresponded with those haplotypes
identified in the three genes analysis and only four had a





02 (1.34%) (Sup. Figure 1).
Identification of homozygous donors
To identify homozygous cord blood units available in
the Spanish banks that can be candidates as source cells
to create the iPSC haplobank, we looked into the
Fig. 1 a Top 30 ranking HLA-A, HLA-B, and HLA-DRB1 estimated
haplotypes by % of frequency at the Spanish Bone Marrow Donor
Registry. b Graphic representation of the % of frequency of the top
100 HLA-A, HLA-B, and HLA-DRB1 estimated haplotypes
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Spanish registry, which comprises 52,220 cord blood do-
nations in Spain. HLA was typed in low resolution (sero-
logical and PCR based) for 42.801 units and high
resolution (NGS) for 9419 units. We identified 322 cord
blood units homozygous for HLA-A, HLA-B, and HLA-
DRB1 (0.62% of the units) representing 111 different
haplotypes (Sup. Figure 2). So far, 109 of the homozy-
gous units were verified by high-resolution HLA typing
and represented 43 different haplotypes. Not to deplete
the cord blood banks of any haplotype for hematopoietic
stem cell transplantation, we only considered those hap-
lotypes with two or more units banked as candidates for
the iPSC bank (Fig. 2). Thirty-one haplotypes were rep-
resented at least twice in low resolution and 11 in high
resolution. The top ten positions in the most frequent
haplotypes from the adult bone marrow donor study
were all represented in at least two units genotyped in
low resolution and nine of them have confirmed units
by high resolution.
Recipients matching coverage
We tested the first 10 most frequent haplotypes for three
genes, HLA-A, HLA-B, and HLA-DRB1, and we found
that the cumulative coverage was 27.84% of the popula-
tion in high resolution and 31.27% in low resolution
(Fig. 3a, b). We also explored the “maximum coverage”
approach for 10 haplolines selecting not the most fre-
quent haplotypes but those that would optimize the
coverage. The choice of haplotypes with this approach
did not change for the top four positions, and the fol-
lowing six, although in a different order, only one new
haplotype was considered: A*02:01~B*18:01~DRB1*03:
01. The cumulative coverage in high resolution was
slightly increased to 28.23% in high resolution and to
31.87% in low resolution (Fig. 3a, b). Since we did not
identify any homozygous cord blood unit in the Spanish
banks with A*02:01~B*18:01~DRB1*03:01, we estimated
the optimized coverage considering only the available
units and then the accumulated coverage in high reso-
lution is 27.95% and 32.58% in low resolution. To calcu-
late how many haplolines would be needed to cover
close to 100% of the Spanish population, we repeated
this iterative process with all the estimated haplotypes in
our study population. We found that 100 haplolines
would cover 65.94% of the Spanish population and that
630 haplolines would be necessary to cover 90% of the
potential recipients (Fig. 3c). We also did this calculation
with 5 genes: HLA-A, HLA-B, HLA-C, HLA-DRB1, and
HLA-DQB1, and then the numbers shift to 100 units to
cover 50% of the population and 897 units needed to
cover 90% (Sup. Figure 3).
Beneficial match
As different iPSC-derived cell types and different en-
graftment sites might present different HLA matching
requirements, we introduced the approach of “beneficial
match” and estimated the coverage in the case that one
or two of the alleles studied did not match as the most
immunogenic of the alleles (Fig. 4). The cumulative
coverage for the top 10 HLA-A, HLA-B, and HLA-
DRB1 haplotypes in the “maximum coverage” list
showed a wide population coverage of 65.9% when
allowing for one mismatch in any of the three alleles
considered and a coverage of 94.81% when allowing to
mismatch in two of the three alleles.
Discussion
Currently, clinical-grade iPSC haplobanks are already
available in South Korea and Japan [19, 20, 26] and simi-
lar initiatives are being undertaken in other countries
such as Australia [27]. The effectiveness of the approach
will come from a global collaborative to share haplolines
and this implies an effort to standardize the production
and quality control by the different banks [28, 29].
Fig. 2 HLA haplotypes and number of units (N.) of HLA-A, HLA-B,
and HLA-DRB1 homozygous found in the Spanish registry of public
cord blood banks and present at least in two units. LR, low
resolution; HR, high resolution
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The IPS-PANIA project aims at developing a haplo-
bank that can serve a significant percentage of the Span-
ish population with HLA-matching iPSC lines that can
be used as starting material for iPSC-derived cell therap-
ies. In the initial phase of the project, we have set a goal
developing seven haplolines.
A previous study of the estimated most frequent hap-
lotypes in the Spanish bone marrow donor database
identified five haplotypes with a frequency ranging from
higher than 1% to the 6th position in the list were the
same as previously described for the Barcelona cord
blood bank study [24]. The differences in the lower posi-
tions might reflect the higher accuracy of the larger
database or geographical or generational differences.
The haplotype with the top frequency is A*29:02~B*44:
03~DRB1*07:01 and the third one A*30:02~B*18:
01~DRB1*03:01 are very common in the western Medi-
terranean region. These haplotypes are less common in
Italy and the rest of south-eastern Europe [30]. A*29:
02~B*44:03~DRB1*07:01 is also a common haplotype in
the Hispanic population in the USA, but less frequent
for European ancestry and extremely rare for Asian
Fig. 3 Estimated percentage and cumulative percentage of HLA-matched individuals in the Spanish population with a panel of 10 homozygous
donors in high resolution (a) and low resolution (b). Estimated numbers of iPSC lines homozygous for HLA-A, HLA-B, and HLA-DRB1 (haplolines)
to cover the Spanish population (c)
Fig. 4 Estimated cumulative percentage of matched individuals in
the Spanish population considering a “beneficial match” with a
panel of 10 homozygous donors from Spanish cord blood Banks in
high resolution allowing for one mismatch in any of the alleles HLA-
A, HLA-B, or HLA-DRB1 (1 MM) or two mismatches (2 MM)
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ancestry [17, 31]. The second and fourth most fre-
quent haplotypes, A*01:01~B*08:01~DRB1*03:01 and
A*03:01~B*07:02~DRB1*15:01 respectively, are among
the most common in the northern and central Euro-
pean population. From the top 10 most frequent hap-
lotypes in Spain, seven are in the top 30 described
for the UK [15]. As expected, they are not identified
with the most frequent haplotypes identified for
Korea and Japan [14, 16].
The identification of homozygous units confirmed that
the Spanish public cord banks contained enough homo-
zygous units that could be used to build an iPSC haplo-
bank to cover the top haplotypes without compromising
the availability of any lifesaving unit needed for
hematopoietic progenitor transplantation. We found a
0.62% of the cord blood units were homozygous, a sig-
nificantly lower number as compared for that reported
for the South Korean population (0.79%), which might
reflect the wider heterogeneity of the HLA genetics in
the Spanish population.
The estimated population coverage of the most fre-
quent haplotypes seems to also reflect a higher HLA
genetic variability in the Spanish population as com-
pared to other populations: the top haplotype in Spain
covers 6.3% and together with the second most frequent
haplotype, the cumulative coverage is 11.2%, while for
Korea, the percentages are 9.2 and 14.5, and for UK,
16.9% and 26.4%. A ten cell line haplobank would cover
28% in four-field resolution and 32% in two-field reso-
lution, while in UK or Japan, the reported coverages for
ten cell lines are closer to 50% of the population. The
“maximum coverage” approach for the selection of the
top ten candidates, opposed to following just the higher
haplotype frequency order, improved the coverage for
the lower positions but the effect was almost lost when
the ten haplolines were considered. When calculating
how many haplotypes would be needed for almost
complete coverage of the Spanish population, we found
that 631 would be needed to cover 90%, again revealing
a much wider variety of existing haplotypes as compared
to other populations analyzed in other studies, such as
Korea that found 90% covered with less than 200 cell
lines [16].
Wider coverage of iPSC haplolines by lowering the
HLA stringency might be worth consideration for an
iPSC bank. It is still early days to know what the real
HLA matching requirements of iPSC derived products
will be as the first clinical trial carried out at the Kobe
City Medical Center in collaboration with Osaka
University, using allogeneic iPSC-derived retinal pigmen-
ted epithelial cells of a HLA-A, HLA-B, HLA-DRB1-
matching haplotype has not been reported yet. It is clear
that HLA matching is advantageous and will reduce the
degree of immunosuppression although this will be
determined by the type of cell and the transplantation
sites. Studies performed in non-human primates match-
ing MHC antigens equivalent to HLA-A, HLA-B, and
HLA-DRB1 have revealed from mild immune infiltration
in iPSC-RPE implanted in the retina [4] to a significant
reaction to the allograft requiring immunosuppression
in the central nervous system [10]. Unlike hematopoietic
progenitors and organ transplants, iPSC-derived cells
will be free of contaminating T cells, except for a small
possibility in the case of hematological lineage deriv-
ation, and no graft-versus-host disease is expected, mak-
ing sense to consider less HLA-match stringent
scenarios closer to solid organ transplants like the kid-
ney. The population coverage when considering haplo-
types in two-field resolution was not much increased as
compared to four-field resolution, highlighting the pre-
dominance of certain subgroups of haplotypes. When
the beneficial match was considered, as expected, the
gains were much greater when allowing for one or two
mismatches in any of the three alleles. The choices of
HLA matching stringency requirements will be deter-
mined by future evidence for the different cell types de-
rived from iPSC and the different transplantation sites.
Taken together, a 30% population match for a ten
cell line haplobank is a significant proportion of po-
tential patients who may benefit from the cell bank.
This justifies the construction of the Spanish haplo-
bank, more so when considering a worldwide effort
to share cells internationally with other banks that
might contain less frequent haplotypes. Also, as the
production of clinical-grade iPSC lines is optimized
and streamlined, it will become easier and more af-
fordable to increase the number of haplolines in the
bank to reach several dozens and cover a much wider
proportion of the population. With this study, we
have investigated the feasibility to provide homozy-
gous cord blood units to create an iPSC bank of a re-
duced number of haplolines that will serve a
significant percentage of the Spanish and international
population. Besides RPE cells for the treatment of
AMD, several other iPSC-derived cells are presently
being tested in clinical trials to treat conditions such
as spinal cord injury, Parkinson’s disease, graft-versus-
host-disease, heart failure, or cancer. Clinical-grade
iPSC are intended to be used as starting material for
future clinical trials and cell therapy products, accel-
erating the application of iPSC-based therapies soon.
Conclusion
With the present study, we have been able to confirm
that HLA homozygous cord blood units stored in Span-
ish cord blood banks can provide for the construction of
an iPSC bank that is useful for a significant part of the
Spanish population (about 28%). The haplotypes
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identified as providing the greatest coverage, may also be
useful for other populations such as Europe and North
America.
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